Iterum raises funds for new antibiotic | Chemical & Engineering News
Volume 95 Issue 22 | pp. 14-15 | Concentrates
Issue Date: May 29, 2017

Iterum raises funds for new antibiotic

Department: Business
Keywords: antibiotics, sulopenem, Iterum, Pfizer

The biotech firm Iterum Therapeutics has raised $65 million in a series B investment round. The cash will help the company complete a Phase III clinical trial of sulopenem, an antibiotic it is developing to treat Gram-negative multi-drug-resistant infections. Iterum was founded in 2015 to license sulopenem from its discoverer, Pfizer. It plans to file a New Drug Application with FDA by the end of 2019.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment